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Abstract 
While the prototype members of the fibroblast growth factor (FGF) family, FGF-1 and FGF-2 are structurally related, the structural 
differences between these polypeptides predict hat they will ultimately exhibit different biological roles. Indeed, a significant difference 
between these proteins is the dependence ofFGF-1 on heparin for the generation of maximal mitogenic activity. In order to gain structural 
insight into the issue of FGF-1 heparin-dependence, a synthetic gene encoding FGF-2 was constructed with oligonucleotides in a 
four-cassette format similar to a synthetic gene previously constructed for FGF-1 (Forough et al. 1992, Biochem. Biophys. Acta 1090 
293-298). This strategy permitted the molecular shuffling of corresponding cassette(s) between FGF-1 and FGF-2 to yield FGF-I :FGF-2 
chimeras. Three amino acid changes (Lys86 ~ Glu, Tyrl20 ~ His, and Thrl21 ~ Ala) were introduced into the synthetic FGF-2 gene by 
the cassette format o generate convenient FGF- 1 restriction sites, but these alterations did not significantly affect he mitogenic activity or 
the heparin-binding affinity of the recombinant FGF-2 protein when compared with native FGF-2. Among the various FGF-I:FGF-2 
chimeric onstructs, one designated FGF-C(I o/2)~ ~), which represents FGF-1 containing FGF-2 amino acid residues 65 to 81, displayed 
FGF- l-like heparin-binding affinity but it did not require the addition of exogenous heparin to manifest i s mitogenic activity. These data 
suggest that the sequence within residues 65 and 81 from FGF-2 significantly contributes to the heparin-dependent character of FGF-1. 
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I. Introduction 
The fibroblast growth factor (FGF) family currently 
consists of nine members including two signal sequence- 
less prototypes, FGF-1 (acidic FGF) and FGF-2 (basic 
FGF) and seven additional members, six of which contain 
a classical signal peptide sequence [ 1-6]. The FGF proto- 
types are also well established as angiogenic and neu- 
Abbreviations: C, chimera; FGF, fibroblast growth factor; ORF, 
open-reading frame; PCR, polymerase chain reaction. 
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rotrophic modulators as well as inducers of mesoderm 
formation during development [7]. The biological activities 
of the FGF prototypes are regulated, in part, by their 
ability to bind to high affinity cell surface receptors [8,9] 
and induce the tyrosine phosphorylation of specific intra- 
cellular polypeptides [ 10-13]. 
Although many of the FGF family members are mito- 
gens for mesoderm- and neuroectoderm-derived c ll types, 
the structural diversity within this gene family ultimately 
predicts specific functions for each member. Indeed, the 
ability of FGF-7 to induce keratinocyte proliferation but 
not fibroblast or endothelial cell growth in vitro is consis- 
tent with the anticipated iversity of function among the 
members of the FGF gene family [2,14]. A unique feature 
which may contribute to this diversity is the dependence of 
FGF-1 on the addition of exogenous heparin for the induc- 
T. lmamura et al. / Biochimica et Biophysica Acta 1266 (1995) 124-130 125 
tion of maximal mitogenic activity [15,16]. This feature is 
not shared by FGF-2 since the mitogenic activity of FGF-2 
is independent of an exogenous heparin supplement [ 17,18]. 
We attempted to study the heparin dependence of FGF-1 
by the construction and expression of recombinant FGF- 
I:FGF-2 chimeric proteins. Our data suggest hat the re- 
gion defined by FGF-2 residues 65 to 81 may significantly 
contribute to the heparin-dependence of FGF-1 since the 
substitution of this region trom FGF-2 into FGF-1 results 
in the formation of a recombinant heparin-independent 
FGF-I :FGF-2 chimera. 
2. Materials and methods 
2.1. Plasmid construction 
FGF-1 was assembled in cassettes as previously de- 
scribed [19]. FGF-2 was constructed using synthetic oligo- 
nucleotides assembled in four cassettes with base modifi- 
cations creating FGF-1 restriction enzyme sites to allow 
for the construction of FGF-1 :FGF-2 chimeric peptides as 
shown in Fig. 1A. Each cassette was constructed by T4 
polynucleotide kinase treatment, annealing of the compli- 
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Fig. l. A: Homology between human FGF-1 and FGF-2. FGF-2 was synthesized in four cassettes (A,B,C,D) ligated together at the indicated restriction 
enzyme sites. The introduction of the FGF-1 restriction enzyme site into the FGF-2 sequence resulted in the amino acid changes indicated above the FGF-2 
protein sequence. FGF-C(to/:) I l) is a FGF-1 chimeric peptide containing FGF-2 amino acids from MunI and NcoI (underlined). The Munl restriction site 
is underlined. B: Structure of the FGF-1 :FGF-2 chimeric (C) proteins. The various chimeric polypeptides were synthesized by cloning the appropriate 
cassette using the indicated restri,:tion sites. Shaded portions in the figure represent FGF-2 cassettes, while open rectangles are FGF-1 cassettes. The NcoI 
site located above residue 1 in cassette A is located in the pUC18 vector. This site was converted into a NdeI site by PCR oligonucleotide mutagenesis for 
expression i  the pET3C system. 
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mentary oligonucleotides, and ligation of the resulting two 
double-stranded oligonucleotides into pUC 18 digested with 
EcoRI  and HindlII.  Cassette A (plasmid pTI1X, Fig. 2) 
oligonucleotides are: 5' sense AATTCCATGGCAGC- 
CGGGAGCATCACCAGCTGCCCCTTGCCCGAGGAT- 
GGCGGCAGCGGCGCCTTC, 3' sense CCGCCCG- 
GCCACTTCAAGGACCCCAAGCGGCTGTACTGCAA- 
AAACGGGGGCTTCTTCCTGCGGATCCCTGCAGCC, 
5' antisense GGGCGGGAAGGCGCCGCTGCCGC-  
CATCCTCGGGCAAGGCGGGCAGCGTGGTGATGCT- 
CCCGGCTGCCATGG, 3' antisense AGCTTGGCTGC- 
AGGGATCCGCAGGAAGAAGCCCCCGTTTTTGCA- 
GTACAGCCGCTTGGGGTCCTTGAAGTGGCC. Cas- 
sette B (pTI2X, Fig. 2) oligonucleotides are: 5' sense 
AATTCGGATCCACCCCGACGGCCGAGTTGACGG- 
GGTCCGGGAGAAGAGCGACCCTCACATCAAGCT- 
ACAACTTCAAGCAG, 3' sense AAGAGAGAGGAG- 
TTGTGTCTATCAAAGGAGTGTGTGCTAACCGTTA- 
CCTGGCCATGGCTGCAGCCA, 5' antisense TCT- 
CTTCTGCTTGAAGTTGTAGCTTGATGTGAGGGT- 
CGCTCTTCTCCCGGACCCCGTCAACTCGGCCGTC- 
GGGGTGGATCCG, 3' antisense AGCTTGGCTGCA- 
GCCATGGCCAGGTAACGGTTAGCACACACTCCTT- 
TGATAGACACAACTCCTC. Cassette C (pTI3X, Fig. 2) 
oligonucleotides are: 5' sense AATTCCATGG-  
AGGAAGATGGAAGATTACTGGCTTCTAAATGTGT- 
TACG, 3' sense GATGAGTGTTTCTTTTTTGAA- 
CGATTGGAATCTAATAACTACAATACTTACCGC- 
TCAAGGAAGCATGCCTGCAGCCA,  5' antisense 
ACTCATCCGTAACACATTTAGAAGCCAGTAATC- 
TTCCATCTTCCTCCATGG, 3' antisense AGCTT- 
GGCTGCAGGCATGCTTCCTTGAGCGGTAAGTAT- 
TGTAGTTATTAGATTCCAATCGTTCAAAAAAGAA- 
AC. Cassette D (pTI4X, Fig. 2) oligonucleotides are: 5' 
Ncol BamHI 
@., 
BamHI Ncol Ncol Sphl 
SspI-BamH Bam~hl  
SspI-BamHI ~Ssp l  
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Fig. 2. Construction pathway of human FGF-2 in the cassette format into pUCI8. Details of the oligonucleotides and cloning are described in Section 2. 
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sense AATTCGCATGCCAGTTGGTATGTGGCACTG- 
AAACGAACTGGGCAGTATAAACTFGGGTCCAAA- 
ACAGGTCCTGGGC, 3' sense AGAAAGCTATACTT- 
TI'TCTTCCAATGTCTGCTAAGAGCTGATTTTAATGG- 
CCAGATCTCTGCAGCCA, 5' antisense CTTTCTGC- 
CCAGGTCCTGTTTTGGACCCAAGTT'I'ATACTGCC- 
CAGTTCGTTTCAGTGCCACATACCAACTGGCAT- 
GCG, 3' antisense AGCTTGGCTGCAGAGATCTG- 
GCCATTAAAATCAGCTCTTAGCAGACATTGGAA- 
GAAAAAGTATAG. The four cassettes were combined as 
described in Fig. 2. The plasmid pTI23X was constructed 
by insertion of the larger Sspl-NcoI fragment of pTI2X 
into the smaller SspI-NcoI fragment of pTI3X. The plas- 
mid pTII23X was constructed by insertion of the larger 
SspI-BamHI fragment of pTI1X into the smaller SspI- 
BamHI fragment of pTI23X. The plasmid, pTI60301, 
which contains the synthetic FGF-2 open-reading frame 
(ORF) was constructed by inserting the larger SspI-SphI 
fragment from pTI123X into the smaller SspI-SphI frag- 
ment of pTI4X. 
The synthetic FGF-2 was cloned into the pET3C ex- 
pression system [20] by the: introduction of a NdeI site at 
the start of the synthetic FGF-2 ORF using polymerase 
chain reaction (PCR) mutagenesis e sentially as described 
[21], but with the 5' oligonucleotide GGCATATG- 
GCAGCCGGGAGCATCACC and 3' oligonucleotide CC- 
CCAGATCTAATCAGCTCTTAGCAGACATTGG (Fig. 
1B). The PCR product was digested with NdeI-BgllI, the 
band isolated, and ligated into the NdeI-BamHI of pET3C 
to form plasmid pTI70301. The FGF-I:FGF-2 chimeric 
peptides were individually constructed using a multi-step 
strategy. Briefly, pTI70308 expressing FGF-C(2111), (the 
lower case number efers ~Lo the ligation of the four cas- 
settes from either synthetic FGF-I(IlI~) or FGF-2 (2222) and 
C represents chimera; Fig. 1B) contains the NcoI-BamHI 
fragment of cassette A inserted into FGF-1 and cloned into 
pET3C in a similar manner as pTI70301. The plasmid 
pTI70405, which expresses FGF-C(1211), contains the 
BamHI-NcoI fragment of cassette B in FGF-1. The plas- 
mid pTI70406, which expresses FGF-C(I~2~), contains the 
Ncol-SphI fragment of cassette C inserted into FGF-1 and 
pTI70407 which expresses FGF-C(t~I2), contains the 
SphI-BgllI fragment of cassette D in FGF-1. The plasmid 
pTI70302, which expresses FGF-C(2122), contains the 
BamHI-NcoI fragment from FGF-1 inserted into FGF-2. 
All these constructs in the pET3C vector were verified by 
sequencing. Construction of SF37 was made by ligation of 
the 5' sense oligonucleotide GATCCTTCCGGATG- 
GCACAGTGGATGGGAC.AAGGGACAGGAGCGACC- 
AGCACATTCAGCTGC, 3' sense oligo A(G ~ A)(C 
T)TGCAAGCAGAAGAGAGAGGAGTTGTGTCTATC- 
AAAGGAGTGTGTGCTAACCGTTACCTGGC, 5' anti- 
sense A(G ~ A)(C ~ T)TGCAGCTGAATGTGCTGGT- 
CGCTCCTGTCCCTTGTCCCATCCACTGTGCCATCC- 
GGAAG and 3' antisense CATGGCCAGGTAACGGTTA- 
GCACACACTCCTTTGATAGACACAACTCCTCTCTC- 
TTCTGCTTGC into the BamHI-NcoI sites of pHBGF-1/3- 
pET3C [19]. The parenthesis in these oligonucleotides 
indicates base changes required to introduce a MunI re- 
striction enzyme site. However, these changes did not 
affect he protein sequence. 
2.2. Expression and purification of FGF-I, FGF-2 and 
FGF-C's 
Purification of the FGF prototype and chimeric (C) 
proteins were performed as previously described [21,22]. 
Briefly, prokaryotic expression of the synthetic FGF-ORFs 
in log phase cultures were induced with 0.5 mM IPTG for 
2 h, cells collected, freeze-thawed in lysis buffer and 
centrifuged. The supernatant was fractionated by heparin- 
Sepharose chromatography, followed by mono-S HPLC 
(Pharmacia). The purity of all recombinant proteins was 
greater than 95% as determined by silver-stained sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis. 
2.3. DNA synthesis assay 
The mitogenic activity of the recombinant FGFs were 
assayed by [3H]thymidine incorporation into DNA in 
BALB/c 3T3 cells as previously described [21]. Briefly, 
subconfluent monolayers of 3T3 cells were starved with 
DMEM containing 0.3% (v/v) charcoal-absorbed fetal 
bovine serum and treated with various concentrations of
the recombinant FGFs. After a 15-h incubation, cells were 
labeled with 2 /xCi/ml [3H]thymidine for 4 h and tri- 
chloroacetic-acid insoluble radioactivity measured. 
2.4. Heparin-Sepharose affinity of recombinant FGF 
chimeric proteins 
The mono-S purified FGF chimeras in 50 mM Tris (pH 
7.4) were loaded onto a HiTrap-heparin (Pharmacia) col- 
umn and eluted with a linear gradient of NaC1 in the same 
buffer. The absorbance at 215 nm of the elution fraction 
was monitored and recorded. 
3. Results and discussion 
FGF-I:FGF-2 chimeric cDNAs were constructed by 
oligonucleotide synthesis of both FGF-1 [19] and FGF-2 in 
a modular cassette strategy (Fig. 2) using FGF-1 restriction 
sites. Although FGF-1 and FGF-2 are 55% structurally 
similar at the amino acid level (Fig. 1A), alteration in 
amino acid residues were introduced into FGF-2 sequence 
for the purpose of creating convenient FGF-1 restriction 
enzyme sites to construct the FGF-I:FGF-2 chimeric cD- 
NAs. The chimeric cDNAs were translated into chimeric 
polypeptides by the pET3C expression system. Mitogenic 
activities of the polypeptides were determined by 
[3H]thymidine incorporation into serum-starved cells. 
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While this strategy results in the three amino acid changes 
in the FGF-2 protein sequence (FGF-C(2222) K86 ~ E, 
YI20 ~ H, T121 ~ A) (Fig. 1A), these changes only re- 
sulted in a minor reduction in the mitogenic activity 
(10-fold) of FGF-C(2222) when compared to wild-type 
FGF-2 (Fig. 3A). In addition, while the mitogenic activity 
of both FGF-C(2222) and wild-type FGF-2 were not depen- 
dent upon the addition of heparin (less than 3-fold; Fig. 
3A), the biological activity of FGF-Coj]I ), which is the 
same protein sequence as wild type, exhibited a strong 
heparin-dependence (Fig. 3B) as previously determined 
[14,17]. 
The FGF chimeric proteins were examined for their 
ability to bind to immobilized heparin. FGF-C(~21), and 
FGF-C(~2) eluted at 0.6 M and 0.8 M NaC1, respectively 
(data not shown), which is less than the elution of their 
wild-type counterparts. Because both chimeric proteins 
exhibited an absence of mitogenic activity at 60 ng/ml in 
the presence of heparin (data not shown), they were deter- 
mined to be unsuitable for further evaluation. Thus, it was 
unfortunate that we were not able to evaluate the potential 
contribution of cassettes C and D to the heparin-dependent 
character of FGF-1. In contrast, FGF-Co21~ ), FGF- 
C(1(1/2)~) (Fig. 4) and FGF-C(2~I) (data not shown) 
demonstrated similar elution profiles from immobilized 
heparin as wild-type FGF-1, thus these chimeric proteins 
retained their FGF-l-like affinity for heparin. 
The mitogenic activity of the chimeric FGF-C(211~) pro- 
tein was also determined (Fig. 3B). Both in the presence or 
absence of heparin, FGF-C(211~) mitogenic activity was 
similar to the heparin dependency of wild-type FGF-I 
(Fig. 3B). The mitogenic activity of FGF-C(]2]I~ was also 
studied and in contrast o the results obtained with FGF- 
C(2111), FGF-C(1211) exhibited no heparin dependence for 
its activity in BALB/c 3T3 cells (Fig. 3C), a characteristic 
that distinguishes between FGF-1 and FGF-2 (Fig. 3A and 
3B). Because the sequence defined by cassette B from 
FGF-1 maybe responsible for the heparin-dependence of 
FGF-1, the second cassette of FGF-1 was placed into 
FGF-2 to form FGF-C~2~22) (Fig. 1B) in order to determine 
whether the mitogenic activity of FGF-2 would become 
heparin-dependent. While FGF-C(2122) eluted from immo- 
bilized heparin near 1.0 M NaCI, a characteristic similar to 
the heparin-binding ability of FGF-1, this protein was not 
stable and was biologically inactive at 60 ng/ml  in the 
presence or absence of heparin (data not shown). 
In order to further define the region in cassette B which 
is responsible for the loss of heparin dependence, cassette 
B was further divided at amino acids 65 to 81 from FGF-2 
(Fig. 1) to form FGF-C(~(~/2)~). As shown in Fig. 3D, the 
mitogenic activity of FGF-C(~ o/2)~ ~) is not dependent upon 
the presence of exogenous heparin. Similarly, a FGF-I 
chimera containing residues 44 to 6l from FGF-2 also 
exhibited heparin dependence for the initiation of DNA 
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Fig. 3. Heparin dependence of FGF-1, FGF-2 and FGF-C's for the initiation of DNA synthesis. [3H]thymidine incorporation into DNA in BALB/c 3T3 
cells was performed with the various recombinant proteins as a function of increasing FGF concentration with and without heparin. A: FGF-C(2222) without 
heparin (11), FGF-C(2222) with heparin (D), native FGF-2 without heparin (O), and native FGF-2 with heparin (O). B: FGF-I without heparin (11), 
FGF-1 with heparin ([]), FGF-C(21 ] i) without heparin (•), FGF-C(21t i)with heparin (~>), (C) FGF-C(] 21~) without heparin (•), FGF-C(~ 211) with heparin 
(~), and FGF-1 with heparin (D). (D) FGF-C(t(I/2)I I)without heparin (•), FGF-Coo/2)~ i) with heparin (O), and FGF-1 with heparin (D). 
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Fig. 4. The heparin-binding affinity of FGF-Co(I/2) 1 I), FGF-C02t l) and 
FGF-1. Elution profiles of chimertc FGF proteins from HiTrap Heparin 
HPLC with a linear NaCI gradient were performed as described in 
Section 2. 
synthesis in Balb/c 3T3 cells (data not shown). These 
results argue that the region in FGF-2 between residues 65 
to 81 is responsible for heparin independence. 
Even though FGF-C¢1(I/2)~I) is heparin-independent, it 
still retains the heparin affinity of FGF-1 and not the 
higher salt elution profile from immobilized heparin which 
is characteristic of FGF-2. Burgess et al. has identified 
lys132 of FGF-1 as a major contributor to heparin-binding 
[23] since a mutation of thi,; conserved residue results in a 
significant reduction in heparin affinity without altering 
receptor binding. In addition, Pineda-Lucena et al. [24] 
have demonstrated that inositol hexasulfate is able to bind 
to residues K126, K127, K~33 and K142 in FGF-2 using 
NMR methods and Li et al. [25] have reported reduced 
heparin affinity and mitogenic activity in two FGF-2 point 
mutants in which K~2 s and K138 were altered. Therefore, 
the domain in FGF-1 and FGF-2 which defines heparin 
affinity is separate from the domain in FGF-1 which 
defines heparin-dependence. In addition, crystallographic 
evidence is consistent with this suggestion since these 
domains are not continuous [26,27]. It is also known that 
the interaction between FGF-1 and heparin is not confined 
to one local domain within FGF-1, since heparin protects 
the entire FGF-1 protein from trypsin digestion [28]. Thus, 
the heparin-binding capability of FGF-I is likely to be a 
function of both the primary and tertiary structure of the 
polypeptide. 
The heparin dependence of FGF-1 for the induction of 
maximal mitogenic activity is a well established criterion 
which has been used to discriminate between FGF-I and 
FGF-2 [ 1,17]. It has been shown that heparin stabilizes the 
tertiary structure of FGF- 1 as determined by thermal denat- 
uration using fluorescence spectroscopy [22,29,30] and 
Dabora et al. [29] have suggested that FGF-1 is unstable at 
a physiological temperature in the absence of heparin. 
Therefore, the heparin requirement for FGF-1 mitogenic 
activity may be explained by stabilization of residues 62 to 
78 in FGF-1 by heparin. Because (1) cells require long-term 
exposure to FGF-1 for the induction of maximal mitogenic 
activity [12], (2) FGF-1 is potentially valuable as a thera- 
peutic for the treatment of wound repair situations in vivo 
and (3) the anti-coagulant activity of heparin may prevent 
the utility of therapeutic FGF-1 in certain situations, the 
availability of a recombinant form of FGF-1 which does 
not require the addition of heparin for the induction of 
biologic responses may represent a valuable alternative for 
clinical studies. 
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